Seattle office could lead research into obesity drugs
Sep 17, 2014, 2:57 PM | Updated: 3:31 pm
A global giant in the treatment of diabetes is looking at Seattle to expand into the treatment of obesity.
Novo Nordisk, the Danish maker of the diabetes drug Victoza, wants to use a higher dosage, injectable version of that drug to treat obesity. FDA approval could happen next month for Saxenda, which the company hopes will generate $1 billion a year.
In an interview with Bloomberg, Chief Science Officer Mads Thomsen says Novo Nordisk could hire as many as 500 people to work out of its Seattle office to do research and development on a portfolio of obesity drugs.
